Positive staining was present in 6.2% of tumours for EGFR, 5.1% of tumours for HER-2/neu, 11.8% tumours for pEGFR, 100% of tumours for total AKT, 8.3% of tumours for pAKT and 36.9% of tumours for pERK (Table 2; Figure 1). This evidence concerns the gene ERBB2 and neoplasm.